RANDOMIZED TRIAL OF HIGH-DOSE CYTARABINE VERSUS AMSACRINE IN ACUTE MYELOGENOUS LEUKEMIA IN RELAPSE - A LEUKEMIA INTERGROUP STUDY

Authors:
  • WVWR VOGLER
    WR VOGLER
  • HPHD PREISLER
    HD PREISLER
  • EWEF WINTON
    EF WINTON
  • AGAJ GOTTLIEB
    AJ GOTTLIEB
  • JGJ GOLDBERG
    J GOLDBERG
  • JBJ BRENNAN
    J BRENNAN
  • HGH GRUNWALD
    H GRUNWALD
  • KRK RAI
    K RAI
  • GBG BROWMAN
    G BROWMAN
  • KMKB MILLER
    KB MILLER
  • PCP CHERVENICK
    P CHERVENICK
  • NAN AZARNIA
    N AZARNIA

  • 1 April 1986
    • journal article
    • research article
    • Vol. 70  (4) , 455-459
    • PMID:3516395
Abstract
Patients with acute myelogenous leukemia in relapse who were ineligible for further anthracycline therapy either because they were judged to be anthracycline resistant or had received the maximum doses were randomized to receive high-dose cytarabine (3 g/m2 every 12 hours for 6 days) or amsacrine (75 mg/m2 daily for 7 days). The response rates in both groups were similar: three of 25 patients given high-dose cytarabine and three of 23 given amsacrine obtained complete remissions.

This publication has 1 reference indexed in Scilit: